发表文章

ASCO 2024 Poster for Abstract # 2575 " Efficacy, Safety, and PK/PD of LVGN6051, 4-1BB agonistic antibody, with pembrolizumab in a Phase Ib dose expansion in resistant NSCLC, Melanoma, and GI malignancy" (Download PDF)

ASCO 2024 Poster for Abstract # 11554 "An open label, phase 1b/2 trial of LVGN6051 (4-1BB agonistic antibody) combined with anlotinib for refractory soft tissue sarcoma (STS)." (Download PDF)

ASCO 2023 Poster for Abstract # 2525 "First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors"(Download PDF)

Liu, L., Y. Wu, K. Ye, M. Cai, G. Zhuang and J. Wang (2022). "Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking." Frontiers in Pharmacology 13. Download PDF

Qi, X., F. Li, Y. Wu, C. Cheng, P. Han, J. Wang and X. Yang (2019). "Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity." Nature Communications 10(1): 2141. Download PDF